Cargando…

Nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis

BACKGROUND: The prognosis of patients with advanced schistosomiasis is poor. Pre-existing prognosis studies did not differentiate the causes of the deaths. The objectives were to evaluate the 2-year overall survival (OS) and advanced schistosomiasis-specific survival (ASS) in patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Guo, Lian, Lifei, Huang, Shanshan, Miao, Jinfeng, Cao, Huan, Zuo, Chengchao, Liu, Xiaoyan, Zhu, Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201698/
https://www.ncbi.nlm.nih.gov/pubmed/32375846
http://dx.doi.org/10.1186/s12967-020-02353-5
_version_ 1783529590793175040
author Li, Guo
Lian, Lifei
Huang, Shanshan
Miao, Jinfeng
Cao, Huan
Zuo, Chengchao
Liu, Xiaoyan
Zhu, Zhou
author_facet Li, Guo
Lian, Lifei
Huang, Shanshan
Miao, Jinfeng
Cao, Huan
Zuo, Chengchao
Liu, Xiaoyan
Zhu, Zhou
author_sort Li, Guo
collection PubMed
description BACKGROUND: The prognosis of patients with advanced schistosomiasis is poor. Pre-existing prognosis studies did not differentiate the causes of the deaths. The objectives were to evaluate the 2-year overall survival (OS) and advanced schistosomiasis-specific survival (ASS) in patients with advanced schistosomiasis after discharge through competing risk analysis and to build predictive nomograms. METHODS: Data was extracted from a previously constructed database from Hubei province. Patients were enrolled from September 2014 to January 2015, with follow up to January 2017. OS and ASS were primary outcome measures. Nomograms for estimating 2-year OS and ASS rates after discharge were established based on univariate and multivariate Cox regression model and Fine and Gray’s model. Their predictive performances were evaluated using C-index and validated in both internal and external validation cohorts. RESULTS: The training cohort included 1487 patients with advanced schistosomiasis. Two-year mortality rate of the training cohort was 8.27% (123/1487). Competing events accounted for 26.83% (33/123). Older age, splemomegaly clinical classification, abnormal serum DBil, AST, ALP and positive HBsAg were significantly associated with 2-year OS. Older age, splemomegaly clinical classification, abnormal serum AST, ALP and positive HBsAg were significantly associated with 2-year ASS. The established nomograms were well calibrated, and had good discriminative ability, with a C-index of 0.813 (95% CI 0.803–0.823) for 2-year OS prediction and 0.834 (95% CI 0.824–0.844) for 2-year ASS prediction. Their predictive performances were well validated in both internal and external validation cohorts. CONCLUSION: The effective predictors of 2-year OS and ASS were discovered through competing risk analysis. The nomograms could be used as convenient predictive tools in clinical practice to guide follow-up and aid accurate prognostic assessment.
format Online
Article
Text
id pubmed-7201698
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72016982020-05-08 Nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis Li, Guo Lian, Lifei Huang, Shanshan Miao, Jinfeng Cao, Huan Zuo, Chengchao Liu, Xiaoyan Zhu, Zhou J Transl Med Research BACKGROUND: The prognosis of patients with advanced schistosomiasis is poor. Pre-existing prognosis studies did not differentiate the causes of the deaths. The objectives were to evaluate the 2-year overall survival (OS) and advanced schistosomiasis-specific survival (ASS) in patients with advanced schistosomiasis after discharge through competing risk analysis and to build predictive nomograms. METHODS: Data was extracted from a previously constructed database from Hubei province. Patients were enrolled from September 2014 to January 2015, with follow up to January 2017. OS and ASS were primary outcome measures. Nomograms for estimating 2-year OS and ASS rates after discharge were established based on univariate and multivariate Cox regression model and Fine and Gray’s model. Their predictive performances were evaluated using C-index and validated in both internal and external validation cohorts. RESULTS: The training cohort included 1487 patients with advanced schistosomiasis. Two-year mortality rate of the training cohort was 8.27% (123/1487). Competing events accounted for 26.83% (33/123). Older age, splemomegaly clinical classification, abnormal serum DBil, AST, ALP and positive HBsAg were significantly associated with 2-year OS. Older age, splemomegaly clinical classification, abnormal serum AST, ALP and positive HBsAg were significantly associated with 2-year ASS. The established nomograms were well calibrated, and had good discriminative ability, with a C-index of 0.813 (95% CI 0.803–0.823) for 2-year OS prediction and 0.834 (95% CI 0.824–0.844) for 2-year ASS prediction. Their predictive performances were well validated in both internal and external validation cohorts. CONCLUSION: The effective predictors of 2-year OS and ASS were discovered through competing risk analysis. The nomograms could be used as convenient predictive tools in clinical practice to guide follow-up and aid accurate prognostic assessment. BioMed Central 2020-05-06 /pmc/articles/PMC7201698/ /pubmed/32375846 http://dx.doi.org/10.1186/s12967-020-02353-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Guo
Lian, Lifei
Huang, Shanshan
Miao, Jinfeng
Cao, Huan
Zuo, Chengchao
Liu, Xiaoyan
Zhu, Zhou
Nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis
title Nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis
title_full Nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis
title_fullStr Nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis
title_full_unstemmed Nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis
title_short Nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis
title_sort nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201698/
https://www.ncbi.nlm.nih.gov/pubmed/32375846
http://dx.doi.org/10.1186/s12967-020-02353-5
work_keys_str_mv AT liguo nomogramstopredict2yearoverallsurvivalandadvancedschistosomiasisspecificsurvivalafterdischargeacompetingriskanalysis
AT lianlifei nomogramstopredict2yearoverallsurvivalandadvancedschistosomiasisspecificsurvivalafterdischargeacompetingriskanalysis
AT huangshanshan nomogramstopredict2yearoverallsurvivalandadvancedschistosomiasisspecificsurvivalafterdischargeacompetingriskanalysis
AT miaojinfeng nomogramstopredict2yearoverallsurvivalandadvancedschistosomiasisspecificsurvivalafterdischargeacompetingriskanalysis
AT caohuan nomogramstopredict2yearoverallsurvivalandadvancedschistosomiasisspecificsurvivalafterdischargeacompetingriskanalysis
AT zuochengchao nomogramstopredict2yearoverallsurvivalandadvancedschistosomiasisspecificsurvivalafterdischargeacompetingriskanalysis
AT liuxiaoyan nomogramstopredict2yearoverallsurvivalandadvancedschistosomiasisspecificsurvivalafterdischargeacompetingriskanalysis
AT zhuzhou nomogramstopredict2yearoverallsurvivalandadvancedschistosomiasisspecificsurvivalafterdischargeacompetingriskanalysis